Schwarz et al. JPGN 2016; 62: 93-96. This study showed that all 21 children who had achieved a sustained virological response with PEG-interferon/ribavirin maintained an SVR during followup of 4.4-7.0 years. Hopefully, new direct-acting highly effective oral agents will be approved in pediatrics and make this study less relevant.
U.S. Food and Drug Administration approved Zepatier (elbasvir and grazoprevir) Jan 28, 2016
Anderson et al. JPGN 2016; 62: 110-17. Participants (n=2612) from a large longitudinal study with prospectively collected data were followed. “The adolescents who are more active in late childhood have lower risk of ultrasound scan fatty liver and lower ϒ-gluamyl transferase levels.” In addition, they showed that more activity was correlated with lower fat mass in adolescence.
Saki et al. JPGN 2016; 62: 97-100. In a double-blind randomized clinical trial of 80 neonates with unconjugated hyperbilirubinemia, treatment with added ursodeoxycholic acid (5 mg/kg/dose BID) resulted in improved clearance of bilirubin compared to phototherapy alone. At 12, 24 and 48 hours, total bilirubin in the treatment group was 12, 10 and 9.8 respectively compared with 14.4, 12.5, and 10.1 for the control group. Furthermore, the mean time for phototherapy to decrease bilirubin to <10 was 15.5 hours in the treatment group compared with 44.6 hours in the control group. This study, if confirmed, could result in shorter hospital stays.